US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

Attana and Triolab sign distribution agreement for all Attana products on the Swedish market

Attana can today announce that the company has signed a distribution agreement with Triolab AB for the marketing and sales of all Attana products on the Swedish market.In June, Attana and Triolab signed a memorandum of understanding (MOU) for the distribution of the newly launched Attana Diagnostics products. Since then, the parties have performed joint sales and marketing activities towards select customers in Sweden. Today, the companies have signed a distribution agreement for the Swedish market which includes all products within both Attana business units: Diagnostics and Life

Release of initial Attana Virus Analytics-AVA testing protocols

Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.In close collaboration with Linnaeus University Attana application specialists have been performing studies on serum samples to detect and characterize COVID-19 antibodies using the Attana Cell™ 200 system. By optimizing the testing procedures, two protocols have now successfully been established and preparations are being made for the scientific publication of corresponding technical notes. The AVA Antibody-Testing protocols are comprised of

Attana launches the Attana Cell 250

Attana has today launched the Attana Cell 250 instrument which features a new and fully integrated autosampler, delivering vastly improved sample handling and instrument operation.Since 2019, Attana has been working closely with ModuVision Technologies BV (Vlissingen, The Netherlands) to integrate their flagship product, the PRIMARIZ robotic autosampler, into the Attana system. The Attana Cell 250 is the first result of this cooperation. “We are proud to welcome Attana to our ever-growing customer base and with this, enter into new application fields,” comments Jan Willem Mol, CEO of

Attana introduces Attana Virus Analytics to support global COVID-19 testing efforts

Since the advent of the COVID-19 outbreak Attana has been engaged by select customers to assist in their development of novel vaccine candidates and potential virus treatments. In these efforts, Attana instruments have routinely been used to analyze serum samples in real time, generating in-depth data of both virus and antibody presence. Given the strong global demand for COVID-19 testing and in particular, accurate antibody testing, Attana has introduced Attana Virus Analytics (AVA) and commenced discussions with various potential customers including international government entities

Potential COVID-19 vaccine passes important milestone

Since March, Attana has been assisting the team of Prof Ali Salanti at the University of Copenhagen in their development of a COVID-19 vaccine together with the Prevent-nCov consortium. Their vaccine is based on the Capsid Virus-Like Particle (cVLP) technology where coronavirus antigens are attached to the cVLP allowing the body’s immune system to respond to the antigens and produce antibodies.During the past two months the vaccine has been tested in mice which produced large amounts of antibodies able to neutralize SARS-CoV-2 virus and the response was several hundred times stronger than

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe